KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Current Assets (2009 - 2026)

Johnson & Johnson recorded quarterly Current Assets of $59.2 billion in Q1 2026, up 6.38% quarter-over-quarter from $55.6 billion in Q4 2025, and down 17.3% year-over-year from $71.6 billion in Q1 2025.

Johnson & Johnson's Current Assets history runs 18 years deep, the most recent figure standing at $59.2 billion for Q1 2026.

  • In Q1 2026, Current Assets fell 17.3% year-over-year to $59.2 billion; the TTM figure through Mar 2026 stood at $59.2 billion (down 17.3% YoY), while the FY2025 annual figure was $55.6 billion, changed 0.48% from the prior year.
  • Current Assets came in at $59.2 billion for Q1 2026 at Johnson & Johnson, up from $55.6 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $71.6 billion in Q1 2025 to a low of $53.2 billion in Q3 2024.
  • A 5-year average of $58.7 billion and a median of $57.4 billion in 2024 frame the typical range for Current Assets.
  • Across the five-year window, Current Assets declined 17.68% in 2023 and advanced 25.52% in 2025, its largest moves.
  • Johnson & Johnson's Current Assets stood at $65.2 billion in 2022, then retreated by 18.0% to $53.5 billion in 2023, then rose by 4.48% to $55.9 billion in 2024, then retreated by 0.48% to $55.6 billion in 2025, then increased by 6.38% to $59.2 billion in 2026.
  • According to Business Quant data, Current Assets over the past three periods registered $59.2 billion, $55.6 billion, and $54.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Assets (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 54.84 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 59.17 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 33.53 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 35.02 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 31.48 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 18.64 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 42.82 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 27.21 Bn
10 Gsk 88.34 Bn 83.66 Bn - 23.29 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 59.17 Bn
Dec 28, 2025 55.62 Bn
Sep 28, 2025 54.61 Bn
Jun 29, 2025 54.50 Bn
Mar 30, 2025 71.55 Bn
Dec 29, 2024 55.89 Bn
Sep 29, 2024 53.25 Bn
Jun 30, 2024 57.82 Bn
Mar 31, 2024 57.00 Bn
Dec 31, 2023 53.50 Bn
Oct 1, 2023 53.70 Bn
Jul 2, 2023 60.57 Bn
Apr 2, 2023 64.39 Bn
Jan 1, 2023 55.29 Bn
Oct 2, 2022 65.24 Bn
Jul 3, 2022 63.85 Bn
Apr 3, 2022 60.42 Bn
Jan 2, 2022 60.98 Bn
Oct 3, 2021 59.89 Bn
Jul 4, 2021 53.77 Bn
Apr 4, 2021 52.53 Bn
Jan 3, 2021 51.24 Bn
Sep 27, 2020 57.58 Bn
Jun 28, 2020 45.89 Bn
Mar 29, 2020 44.23 Bn
Dec 29, 2019 45.27 Bn
Sep 29, 2019 44.33 Bn
Jun 30, 2019 41.80 Bn
Mar 31, 2019 41.99 Bn
Dec 30, 2018 46.03 Bn
Sep 30, 2018 47.19 Bn
Jul 1, 2018 45.44 Bn
Apr 1, 2018 42.77 Bn
Dec 31, 2017 43.09 Bn
Oct 1, 2017 41.83 Bn
Jul 2, 2017 38.79 Bn
Apr 2, 2017 63.35 Bn
Jan 1, 2017 65.03 Bn
Oct 2, 2016 63.32 Bn
Jul 3, 2016 66.29 Bn
Apr 3, 2016 62.74 Bn
Jan 3, 2016 60.21 Bn
Sep 27, 2015 63.49 Bn
Jun 28, 2015 61.00 Bn
Mar 29, 2015 58.19 Bn
Dec 28, 2014 55.74 Bn
Sep 28, 2014 59.97 Bn
Jun 29, 2014 60.12 Bn
Mar 30, 2014 57.37 Bn
Dec 29, 2013 56.41 Bn
Sep 29, 2013 52.18 Bn
Jun 30, 2013 51.27 Bn
Mar 31, 2013 47.23 Bn
Dec 30, 2012 46.12 Bn
Sep 30, 2012 44.79 Bn
Jul 1, 2012 41.62 Bn
Apr 1, 2012 57.01 Bn
Jan 1, 2012 54.32 Bn
Oct 2, 2011 53.44 Bn
Jul 3, 2011 52.67 Bn
Apr 3, 2011 49.22 Bn
Jan 2, 2011 47.31 Bn
Oct 3, 2010 42.72 Bn
Jul 4, 2010 39.02 Bn
Apr 4, 2010 38.86 Bn
Jan 3, 2010 39.54 Bn
Sep 27, 2009 35.60 Bn
Jun 28, 2009 35.49 Bn